Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8273a + nivolumab in advanced colorectal cancer
NCT02991196Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-8273a in colorectal cancer (CRC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 28 days, Clinically Significant Safety Parameters at 2 years and 8 more. Started Dec 2016; status: terminated.
02
Drugs
DS-8273a
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02991196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991196.